MetaCap

BioVie (BIVI) vs Lexaria Bioscience (LEXX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie is the larger company by market cap ($8.6 million vs $8.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-42.86%LEXX+16.47%
+39%-4%-47%
Oct 7, 20261 yearNov 20, 2026
BIVI-42.45%LEXX+21.39%
+39%-3%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus LEXX key metrics
MetricBIVILEXX
Share price$0.80$4.03
Market cap$8.58M$8.49M
1-day change-12.07%-10.24%
YTD return-31.03%—
1-year return-38.22%—
5-year return-99.87%—
EPS (TTM)$-2.85$-5.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$705.92K
Revenue growth (YoY)—+52.05%
Net income (latest FY)$-22.07M$-11.90M
Gross margin—99.61%
Operating margin—-1683.01%
Net margin—-1686.00%
52-week high$3.79$21.60
52-week low$0.7515$2.43
Distance from 52-week high-78.89%-81.34%
Analyst consensusnonenone
Avg. price target upside+557.50%+1947.15%
Average volume568.61K70.52K
Shares outstanding10.72M2.11M
Employees137
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

BIVI vs LEXX FAQ

Which is bigger, BioVie or Lexaria Bioscience?

BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.49M for Lexaria Bioscience (LEXX).

Are BioVie and Lexaria Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons